(Q46974749)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

main subject

phase II clinical trial

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Claire F. Verschraegen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Edward Neely Atkinson

7

object named as

Neely Atkinson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

8

David M Gershenson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Judith K Wolf

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Charlotte C Sun

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Donna Branham

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Alfred D Jenkins

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

3 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

468-474

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

The cancer patient and quality of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Patient preferences for oral versus intravenous palliative chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Reliability and validity of the functional assessment of cancer therapy-ovarian.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2005.12.040

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16516276%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference